



## **Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference**

January 3, 2023

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema", "Olema Oncology", Nasdaq: OLMA) today announced that Sean Bohan, M.D., President and Chief Executive Officer, will present at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET).

A live webcast of the presentation and any accompanying presentation materials will be available under the News & Events section of Olema's Investor Relations website at [www.olema.com](http://www.olema.com). The webcast will be archived for at least 30 days.

### **About Olema Oncology**

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

### **IR Contact:**

Courtney Dugan, Vice President, Investor Relations and Communications  
[ir@olema.com](mailto:ir@olema.com)

### **Media Contact:**

Ignacio Guerrero-Ros, Ph.D., Russo Partners  
646-942-5604  
[ignacio.guerrero-ros@russopartnersllc.com](mailto:ignacio.guerrero-ros@russopartnersllc.com)